```mermaid
flowchart TD
Notch["Notch"]
Delta__Serrate__Lag_2["Delta, Serrate, Lag-2"]
Notch -->|"binds"| Delta__Serrate__Lag_2
CSL["CSL"]
Notch -->|"binds"| CSL
Transcription["Transcription"]
Notch -->|"activates"| Transcription
Notch_Target_Genes["Notch Target Genes"]
Notch -->|"regulates"| Notch_Target_Genes
Delta["Delta"]
Notch -->|"associated with"| Delta
Cancer["Cancer"]
Cancer -->|"therapeutic_target"| Notch
Als["Als"]
Als -->|"therapeutic_target"| Notch
CANCER["CANCER"]
CANCER -->|"therapeutic_target"| Notch
Tumor["Tumor"]
Tumor -->|"therapeutic_target"| Notch
Inflammation["Inflammation"]
Inflammation -->|"therapeutic_target"| Notch
NOTCH1["NOTCH1"]
NOTCH1 -.->|"inhibits"| Notch
GENES["GENES"]
GENES -->|"regulates"| Notch
style Notch fill:#4a148c,stroke:#ce93d8,color:#ce93d8
style Delta__Serrate__Lag_2 fill:#263238,stroke:#90a4ae,color:#90a4ae
style CSL fill:#263238,stroke:#90a4ae,color:#90a4ae
style Transcription fill:#263238,stroke:#90a4ae,color:#90a4ae
style Notch_Target_Genes fill:#263238,stroke:#90a4ae,color:#90a4ae
style Delta fill:#263238,stroke:#90a4ae,color:#90a4ae
style Cancer fill:#4a0000,stroke:#ef5350,color:#ef5350
style Als fill:#4a0000,stroke:#ef5350,color:#ef5350
style CANCER fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style Tumor fill:#4a0000,stroke:#ef5350,color:#ef5350
style Inflammation fill:#4a0000,stroke:#ef5350,color:#ef5350
style NOTCH1 fi
Knowledge graph relationships for Notch (857 total edges in KG)
Notch Signaling in Parkinson's Disease describes the role of the Notch signaling pathway in PD pathogenesis and its potential as a therapeutic target. The Notch pathway is a highly conserved cell-cell communication mechanism that regulates neurodevelopment, neural stem cell maintenance, and neuronal survival[@lasky2020]. In PD, Notch signaling intersects with key pathological processes including [alpha-synuclein](/proteins/alpha-synuclein) aggregation, dopaminergic neuron degeneration, neuroinflammation, and mitochondrial dysfunction[@luo2019][@sharma2019].
The Notch pathway has emerged as a critical regulator of neurodegenerative processes through its roles in neural development, synaptic plasticity, and cellular stress responses[@liu2019]. Understanding Notch signaling in PD provides insights into disease mechanisms and potential therapeutic interventions targeting this evolutionarily conserved pathway[@song2020].
The Notch family consists of four receptors (Notch1-4) and multiple ligands (Jagged1, Jagged2, DLL1, DLL3, DLL4). Upon ligand binding[@lasky2020]:
The Notch receptors are single-pass transmembrane proteins that require proteolytic processing for activation[@geva2020]. The extracellular domain contains epidermal growth factor-like repeats that mediate ligand binding, while the intracellular domain contains the transcriptional activation domain[@hori2018].
| Receptor | Expression Pattern | Ligands | Key Functions |
|----------|-------------------|---------|----------------|
| Notch1 | Neural stem cells, neurons | Jagged1, DLL1 | Neurogenesis, synaptic plasticity |
| Notch2 | Microglia, astrocytes | Jagged1, DLL3 | Glial development, inflammation |
| Notch3 | Vascular cells, neurons | Jagged2, DLL1 | Blood-brain barrier, neuronal survival |
| Notch4 | Endothelial cells | DLL4 | Vascular development |
Beyond canonical γ-secretase-dependent signaling, Notch receptors can signal through non-canonical pathways independent of proteolytic cleavage[@andersson2018]. These include:
Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable due to their unique physiological characteristics[@luo2019]. Notch signaling plays a critical role in dopaminergic neuron development and survival:
Emerging evidence suggests crosstalk between Notch signaling and [alpha-synuclein](/proteins/alpha-synuclein) pathology[@sharma2019][@xia2018]:
Key mechanisms:
Notch signaling interacts with neuroinflammatory processes in PD[@liu2019][@song2020]:
The Notch-NF-κB cross-talk represents a key intersection between neuroinflammation and Notch signaling in PD. Microglial activation leads to pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), which can activate Notch signaling in neighboring neurons and glia[@sestan2018].
Key inflammatory interactions:
Notch signaling impacts mitochondrial function in dopaminergic neurons[@wang2016]:
Mitochondrial Dynamics: Notch signaling influences mitochondrial fission/fusion dynamics through regulation of Drp1, Mfn1/2, and OPA1[@zhang2017]. Dysregulation of these processes leads to fragmented mitochondria and impaired function in PD models[@huang2015].
ATP Production: Notch modulates expression of metabolic genes including those involved in oxidative phosphorylation. In PD models, Notch inhibition improves mitochondrial respiration in dopaminergic neurons[@liu2018].
ROS Metabolism: Notch signaling regulates antioxidant response genes including Nrf2 target genes. The crosstalk between Notch and Nrf2 pathways influences neuronal susceptibility to oxidative stress[@wakabayashi2014].
Mitophagy: The PINK1/Parkin-mediated mitophagy pathway intersects with Notch signaling. Notch can modulate clearance of damaged mitochondria, and conversely, mitochondrial dysfunction can affect Notch activity[@park2018].
Notch signaling intersects with endoplasmic reticulum stress pathways relevant to PD[@geva2020][@yoshida2016]:
Notch signaling influences calcium homeostasis in neurons[@shankar2015]:
| Compound | Mechanism | Development Stage | Evidence |
|----------|-----------|-------------------|----------|
| DAPT | γ-secretase inhibitor | Preclinical | Reduces α-syn toxicity in models[@pan2020] |
| GSI-IX | γ-secretase inhibitor | Preclinical | Improves motor function in PD models[@song2019a] |
| DBZ | γ-secretase inhibitor | Preclinical | Neuroprotective in MPTP models[@liu2015] |
| Jagged1 peptide | Notch ligand agonist | Research | Promotes neuronal survival[@zhang2019] |
| MK-0752 | γ-secretase inhibitor | Clinical (cancer) | Potential repurposing for PD |
Gamma-secretase inhibitors (GSIs) have been extensively studied in PD models[@schliebs2012]. However, GSIs face challenges due to the pleiotropic functions of γ-secretase and potential side effects from Notch inhibition[@bittner2016]. Selective targeting of Notch over other γ-secretase substrates remains an active research area.
Rather than inhibition, some therapeutic approaches aim to modulate Notch signaling toward neuroprotective states[@liu2018a]:
Post-mortem studies of PD patient brains have revealed:
Induced pluripotent stem cell models of PD have demonstrated[@song2019][@sonn2019]:
MPTP and 6-OHDA models show[@cheng2014][@liu2014]:
The Notch pathway presents therapeutic challenges[@kopan2012]:
Optimal timing for Notch-targeted interventions[@kelleher2015]:
Complete Notch inhibition may cause[@shih2011]:
Notch signaling shows distinct patterns in AD compared to PD[^40]:
| Feature | Alzheimer's Disease | Parkinson's Disease |
|---------|--------------------|--------------------|
| Primary pathology | Amyloid-β, Tau | α-Synuclein |
| Notch alteration | Upregulated in early stages | Dysregulated in later stages |
| Therapeutic target | γ-secretase modulators | Notch immunomodulation |
| Neuronal vulnerability | Cortical neurons | Dopaminergic neurons |
In AD, Notch signaling is particularly active during amyloid-beta plaque formation, while in PD the alterations are more closely tied to protein aggregation and neuroinflammation[@park2016].
Notch signaling in ALS shows unique characteristics[^42]:
Genome-wide association studies have identified potential links between Notch gene variants and PD risk[^43]:
Notch signaling intersects with familial PD genes[^44]:
Potential Notch-based biomarkers for PD[^45]:
Emerging strategies for Notch-targeted PD therapy[^46]:
Future directions include[^47]:
Key models for studying Notch in PD[^48]:
| Model | Application | Limitations |
|-------|-------------|-------------|
| MPTP model | Acute dopaminergic degeneration | Non-progressive |
| 6-OHDA model | Unilateral lesions | Unilateral degeneration |
| Alpha-synuclein transgenic | Protein aggregation | Variable phenotype |
| Notch conditional KO | Pathway-specific effects | Developmental confound |
Cellular models for Notch-PD research[^49]:
Potential endpoints for Notch-targeted trials[^50]:
Notch and Wnt signaling interact in PD[^51]:
Notch-Hh interactions in PD[^52]:
Notch-PI3K/Akt interactions[^53]:
[@park2016]: Park SH, et al. [Amyloid-beta and Notch signaling crosstalk](https://pubmed.ncbi.nlm.nih.gov/27515308/). Nat Rev Neurosci. 2016;17(8):485-497.
Notch signaling intersects with circadian rhythm pathways[- Notch regulates clock gene expression
Notch signaling represents a promising therapeutic target in Parkinson's disease through its involvement in multiple pathogenic pathways. The crosstalk between Notch and alpha-synuclein pathology, neuroinflammation, mitochondrial dysfunction, and ER stress provides multiple intervention points. While gamma-secretase inhibitors have shown preclinical promise, selective Notch modulation remains a key challenge due to the pathway's pleiotropic functions throughout the body.
Future research directions include:
The translation of Notch research from preclinical models to clinical applications requires careful consideration of patient selection, outcome measures, and long-term safety monitoring.
The Notch signaling pathway in Parkinson's disease represents a complex interplay of development, neurodegeneration, and neuroinflammation. As research progresses, Notch-based therapies may provide disease-modifying benefits by targeting multiple pathological pathways simultaneously. However, the challenge## Key Takeaways
The following diagram shows the key molecular relationships involving Notch Signaling in Parkinson's Disease discovered through SciDEX knowledge graph analysis: